MoonLake Immunotherapeutics (MLTX)
Nasdaq · Healthcare · Biotechnology
$11.38−0.26%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $969M
- 52-week range
- $8.18 – $23.29
- 52-week change
- +22.95%
- EPS (trailing)
- −$3.83
- Analyst rating
- 1.9 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$227M
- Diluted EPS
- −$3.53
- Free cash flow
- −$196M
From the company’s annual report on SEC EDGAR.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Headquarters: Zug, Switzerland · 130 employees · moonlaketx.com